FibroBiologics CEO Issues Letter to Shareholders
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG) announced initiation of its clinical trial for lead program CYWC628, an investigational fibroblast-based therapy for diabetic foot ulcers. The company completed initial site activation and plans patient enrollment in Q2 2026 with topline data expected by end of 2026.
Management says its capital plan funds operations through the topline readout and highlights ongoing preclinical programs in multiple sclerosis, psoriasis, and an artificial thymus organoid platform.
AI-generated analysis. Not financial advice.
Positive
- Clinical trial initiated for CYWC628 targeting diabetic foot ulcers
- Patient enrollment scheduled to begin in Q2 2026
- Topline data expected by end of 2026
- Capital plan said to fund operations through topline data
Negative
- No clinical efficacy or safety data yet for CYWC628
- Other programs (MS, psoriasis, thymus organoid) remain in preclinical stages
News Market Reaction – FBLG
On the day this news was published, FBLG declined 3.62%, reflecting a moderate negative market reaction. Argus tracked a peak move of +12.9% during that session. Argus tracked a trough of -7.6% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $252K from the company's valuation, bringing the market cap to $6.72M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
FBLG was down 5.48% with elevated volume, while closely scored biotech peers were mixed: names like CRIS and NRXS were up modestly and ICU, LIXT were slightly down. Momentum scanners only flagged QTTB moving up, reinforcing that today’s weakness appears stock-specific rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 04 | Clinical trial supply | Positive | -5.5% | First cGMP CYWC628 batch released to enable DFU Phase 1/2 trial. |
| Apr 30 | Earnings & update | Neutral | +10.6% | Q1 2026 loss, low cash, capital raises and CYWC628 progress detailed. |
| Apr 30 | Conference poster | Positive | +0.8% | Announcement of CYPS317 psoriasis data poster at dermatology meeting. |
| Apr 20 | Nasdaq compliance | Positive | -0.7% | Regained compliance with Nasdaq equity and $1.00 bid price rules. |
| Apr 10 | Preclinical data | Positive | -2.2% | Thymus organoid platform showed restored immune function in mice. |
Recent news has generally been positive operationally, but price reactions have been mixed, with several scientific and compliance updates followed by flat or negative moves.
Over the last month, FibroBiologics issued multiple updates around its fibroblast-based pipeline and listing status. On Apr 10, preclinical thymus organoid data was followed by a -2.17% move. A Nasdaq compliance confirmation on Apr 20 saw shares slip -0.65%. Q1 2026 results and a corporate update on Apr 30 coincided with a 10.61% gain, while a psoriasis poster announcement the same day saw a modest 0.76% rise. The May 4 CYWC628 drug product release for a DFU trial preceded a -5.48% decline, indicating that even constructive clinical milestones have not consistently driven upside.
Market Pulse Summary
This announcement outlines FibroBiologics’ transition into clinical execution, highlighting initiation of the CYWC628 trial for diabetic foot ulcers, with enrollment targeted in Q2 2026 and a topline readout by year-end 2026. Management states that the current capital plan funds operations through that readout, while also advancing programs in multiple sclerosis, psoriasis, and an artificial thymus organoid platform. In evaluating this update, investors may weigh these milestones alongside prior filings detailing losses, cash levels, and use of equity financing.
Key Terms
fibroblasts medical
fibroblast-derived materials medical
clinical trial medical
diabetic foot ulcers medical
immune-modulating medical
topline data readout technical
artificial thymus organoid medical
AI-generated analysis. Not financial advice.
HOUSTON, May 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today issued the following letter to shareholders.
Dear Fellow Shareholders,
This year, FibroBiologics achieved a milestone we have been working toward over the past few years. We initiated our clinical trial for our lead program, CYWC628, an investigational fibroblast-based therapy for diabetic foot ulcers (DFUs).
After years of building the technology and infrastructure to support it, progressing into the clinic is a critical step for us. It demonstrates the dedicated work across the team and signifies an important transition from development into clinical execution.
DFUs remain an underserved condition in medicine. More than 33 million patients worldwide are affected, yet current treatment options continue to fall short, with amputation and recurrence rates that have seen little improvement over time. CYWC628 is designed to address this by harnessing the unique regenerative and immune-modulating properties of fibroblasts. We are now evaluating its clinical benefit potential in patients. This program represents not only a near-term opportunity, but also a first step in demonstrating the broader applicability of our platform and the potential to derisk for future indications and applications.
We have a clear set of imminent clinical milestones that will guide this program. We have completed initial site activation and will begin patient enrollment in Q2 of 2026. Our focus will be on generating data that validates the efficacy and safety as the trial progresses, resulting in a topline data readout that can inform the next phase of clinical development by the end of 2026. Each of these steps is designed to reduce risk and build a strong clinical foundation for CYWC628.
Our current capital plan provides us with the resources to operate through topline data from this trial. This allows our team to remain focused on disciplined execution by advancing the study, generating high-quality data, and reaching a meaningful clinical readout.
While CYWC628 is our priority, we continue to progress across the broader pipeline. Our programs in multiple sclerosis and psoriasis are advancing, supported by ongoing preclinical work, and our artificial thymus organoid platform continues to generate data that we believe may support an entirely new approach to restoring immune function. Each of these programs reflects our strategy of targeting diseases where cellular dysfunction plays a central role and where our technology may offer a differentiated approach.
Last year, I said we were building something enduring. This year, we are beginning to demonstrate it with a clear clinical pathway, a focused strategy, and the resources to execute.
Thank you for your continued support and confidence in what we are building.
Best regards,
Pete O’Heeron
Founder, Chief Executive Officer, and Chairman
FibroBiologics
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.
Cautionary Statement Regarding Forward-Looking Statements
This letter contains "forward-looking statements." Forward-looking statements include information concerning plans for, the anticipated timing of the initiation of, and reporting of results from, FibroBiologics’ clinical trials, the robustness, progress, timing, and momentum of FibroBiologics’ research and development program, the potential, capabilities, and potential applications of fibroblasts and fibroblast-derived materials, the potential of FibroBiologics’ platform, indications of interest, and the sufficiency of capital resources. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; (d) the ability of FibroBiologics to successfully prosecute its patent applications; (e) FibroBiologics’ ability to manufacture its product candidates; and (f) FibroBiologics’ ability to conduct clinical trials. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f3ebedd0-66f2-4e20-b298-4b52bbb42404
